<DOC>
	<DOCNO>NCT01249118</DOCNO>
	<brief_summary>The primary objective Part 1 study evaluate safety tolerability intravenous ( IV ) dose GDC-0973 . The primary objective Part 2 study evaluate absolute bioavailability GDC-0973 evaluate pharmacokinetic ( PK ) GDC-0973 follow IV oral administration . The secondary objective Part 2 study evaluate safety GDC-0973 administer orally intravenously .</brief_summary>
	<brief_title>An Absolute Bioavailability Study Healthy Participants Comparing Oral Intravenous Administration GDC-0973 ( Cobimetinib )</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Within body mass index range 18.5 29.9 kilogram per square meter ( kg/m^2 ) In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign Clinical laboratory evaluation within reference range test laboratory Negative test select drug abuse Screening Checkin Negative hepatitis panel antihepatitis C virus negative human immunodeficiency virus ( HIV ) antibody screen Healthy male females nonchildbearing potential agree use effective contraception Exclusion Criteria Significant history clinical manifestation significant metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder History significant hypersensitivity , intolerance , allergy drug compound , food , substance History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy , hernia repair , cholecystectomy allow History presence abnormal ECG History alcoholism drug addiction prior period 1 checkin Use tobaccocontaining nicotinecontaining product prior period 1 checkin Participation investigational study drug trial receipt investigational study drug occur within 28 day 5 halflives , whichever longer , prior period 1 checkin Use prescription medications/products , include proton pump inhibitor , within 14 day prior period 1 checkin Poor peripheral venous access Any acute chronic condition would limit participant ability complete and/or participate clinical study Female participant pregnant , lactating , breastfeed Predisposing factor retinal vein occlusion ( RVO )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>